Dec. 5, 2007 - Keryx Biopharmaceuticals (Nasdaq: KERX) announced that the Independent Data Safety Monitoring Committee (DSMC) responsible for monitoring Sulonex(TM) (sulodexide oral gelcaps), the Company's lead drug candidate under development as a treatment for diabetic nephropathy , recently met to evaluate the data from the ongoing Phase 3 trial... Keryx Biopharmaceuticals' Press Release -Thursday, December 20, 2007
Keryx , Sulodexide Phase 3 study to continue without modification
Dec. 5, 2007 - Keryx Biopharmaceuticals (Nasdaq: KERX) announced that the Independent Data Safety Monitoring Committee (DSMC) responsible for monitoring Sulonex(TM) (sulodexide oral gelcaps), the Company's lead drug candidate under development as a treatment for diabetic nephropathy , recently met to evaluate the data from the ongoing Phase 3 trial... Keryx Biopharmaceuticals' Press Release -
